Cargando…

The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis

BACKGROUND: Diastolic left ventricular (LV) dysfunction appears more prevalent in ankylosing spondylitis (AS). The effects of tumor necrosis factor alpha (TNF-α) blocking therapy, a strong and effective anti-inflammatory drug, on diastolic LV function in AS are unknown. The objective of the study wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Heslinga, SC, Konings, TC, van der Horst-Bruinsma, IE, Kamp, O, van Halm, VP, de Bruin-Bon, HACM, Peters, MJ, Nurmohamed, MT
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231442/
https://www.ncbi.nlm.nih.gov/pubmed/30510398
http://dx.doi.org/10.2147/BTT.S176806
_version_ 1783370222755905536
author Heslinga, SC
Konings, TC
van der Horst-Bruinsma, IE
Kamp, O
van Halm, VP
de Bruin-Bon, HACM
Peters, MJ
Nurmohamed, MT
author_facet Heslinga, SC
Konings, TC
van der Horst-Bruinsma, IE
Kamp, O
van Halm, VP
de Bruin-Bon, HACM
Peters, MJ
Nurmohamed, MT
author_sort Heslinga, SC
collection PubMed
description BACKGROUND: Diastolic left ventricular (LV) dysfunction appears more prevalent in ankylosing spondylitis (AS). The effects of tumor necrosis factor alpha (TNF-α) blocking therapy, a strong and effective anti-inflammatory drug, on diastolic LV function in AS are unknown. The objective of the study was to find the effects of 1-year treatment with golimumab 50 mg subcutaneously once per month on systolic and diastolic LV dysfunction in AS patients. METHODS: Forty consecutive AS patients were treated with TNF-α blocking therapy for 1 year. Transthoracic echocardiography was performed in all patients at baseline and after 1 year of treatment. RESULTS: Diastolic LV function improved after treatment in four out of six (67%) AS patients who completed follow-up (P=0.125), and did not develop or worsen in any of the other patients. Treatment with TNF-α blocking therapy had no effect on systolic LV function. CONCLUSION: These findings give support to the hypothesis that diastolic LV dysfunction improves during treatment with TNF-α blocking therapy.
format Online
Article
Text
id pubmed-6231442
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62314422018-12-03 The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis Heslinga, SC Konings, TC van der Horst-Bruinsma, IE Kamp, O van Halm, VP de Bruin-Bon, HACM Peters, MJ Nurmohamed, MT Biologics Original Research BACKGROUND: Diastolic left ventricular (LV) dysfunction appears more prevalent in ankylosing spondylitis (AS). The effects of tumor necrosis factor alpha (TNF-α) blocking therapy, a strong and effective anti-inflammatory drug, on diastolic LV function in AS are unknown. The objective of the study was to find the effects of 1-year treatment with golimumab 50 mg subcutaneously once per month on systolic and diastolic LV dysfunction in AS patients. METHODS: Forty consecutive AS patients were treated with TNF-α blocking therapy for 1 year. Transthoracic echocardiography was performed in all patients at baseline and after 1 year of treatment. RESULTS: Diastolic LV function improved after treatment in four out of six (67%) AS patients who completed follow-up (P=0.125), and did not develop or worsen in any of the other patients. Treatment with TNF-α blocking therapy had no effect on systolic LV function. CONCLUSION: These findings give support to the hypothesis that diastolic LV dysfunction improves during treatment with TNF-α blocking therapy. Dove Medical Press 2018-11-08 /pmc/articles/PMC6231442/ /pubmed/30510398 http://dx.doi.org/10.2147/BTT.S176806 Text en © 2018 Heslinga et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Heslinga, SC
Konings, TC
van der Horst-Bruinsma, IE
Kamp, O
van Halm, VP
de Bruin-Bon, HACM
Peters, MJ
Nurmohamed, MT
The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis
title The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis
title_full The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis
title_fullStr The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis
title_full_unstemmed The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis
title_short The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis
title_sort effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231442/
https://www.ncbi.nlm.nih.gov/pubmed/30510398
http://dx.doi.org/10.2147/BTT.S176806
work_keys_str_mv AT heslingasc theeffectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis
AT koningstc theeffectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis
AT vanderhorstbruinsmaie theeffectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis
AT kampo theeffectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis
AT vanhalmvp theeffectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis
AT debruinbonhacm theeffectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis
AT petersmj theeffectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis
AT nurmohamedmt theeffectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis
AT heslingasc effectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis
AT koningstc effectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis
AT vanderhorstbruinsmaie effectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis
AT kampo effectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis
AT vanhalmvp effectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis
AT debruinbonhacm effectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis
AT petersmj effectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis
AT nurmohamedmt effectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis